264 related articles for article (PubMed ID: 17606376)
1. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
2. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.
Levin JI; Chen JM; Du MT; Nelson FC; Killar LM; Skala S; Sung A; Jin G; Cowling R; Barone D; March CJ; Mohler KM; Black RA; Skotnicki JS
Bioorg Med Chem Lett; 2002 Apr; 12(8):1199-202. PubMed ID: 11934588
[TBL] [Abstract][Full Text] [Related]
3. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
Levin JI; Chen JM; Laakso LM; Du M; Schmid J; Xu W; Cummons T; Xu J; Jin G; Barone D; Skotnicki JS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1605-9. PubMed ID: 16426848
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.
Mazzola RD; Zhu Z; Sinning L; McKittrick B; Lavey B; Spitler J; Kozlowski J; Neng-Yang S; Zhou G; Guo Z; Orth P; Madison V; Sun J; Lundell D; Niu X
Bioorg Med Chem Lett; 2008 Nov; 18(21):5809-14. PubMed ID: 18835710
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.
Zhang C; Lovering F; Behnke M; Zask A; Sandanayaka V; Sun L; Zhu Y; Xu W; Zhang Y; Levin JI
Bioorg Med Chem Lett; 2009 Jul; 19(13):3445-8. PubMed ID: 19464885
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.
Lombart HG; Feyfant E; Joseph-McCarthy D; Huang A; Lovering F; Sun L; Zhu Y; Zeng C; Zhang Y; Levin J
Bioorg Med Chem Lett; 2007 Aug; 17(15):4333-7. PubMed ID: 17531482
[TBL] [Abstract][Full Text] [Related]
7. Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.
Levin JI; Chen JM; Cheung K; Cole D; Crago C; Santos ED; Du X; Khafizova G; MacEwan G; Niu C; Salaski EJ; Zask A; Cummons T; Sung A; Xu J; Zhang Y; Xu W; Ayral-Kaloustian S; Jin G; Cowling R; Barone D; Mohler KM; Black RA; Skotnicki JS
Bioorg Med Chem Lett; 2003 Aug; 13(16):2799-803. PubMed ID: 12873518
[TBL] [Abstract][Full Text] [Related]
8. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sheppeck JE; Gilmore JL; Tebben A; Xue CB; Liu RQ; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 May; 17(10):2769-74. PubMed ID: 17368021
[TBL] [Abstract][Full Text] [Related]
9. Conversion of potent MMP inhibitors into selective TACE inhibitors.
Cherney RJ; King BW; Gilmore JL; Liu RQ; Covington MB; Duan JJ; Decicco CP
Bioorg Med Chem Lett; 2006 Feb; 16(4):1028-31. PubMed ID: 16289878
[TBL] [Abstract][Full Text] [Related]
10. A molecular modeling analysis of novel non-hydroxamate inhibitors of TACE.
Sheppeck JE; Tebben A; Gilmore JL; Yang A; Wasserman ZR; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 Mar; 17(5):1408-12. PubMed ID: 17188861
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
Cherney RJ; Duan JJ; Voss ME; Chen L; Wang L; Meyer DT; Wasserman ZR; Hardman KD; Liu RQ; Covington MB; Qian M; Mandlekar S; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2003 May; 46(10):1811-23. PubMed ID: 12723945
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.
Venkatesan AM; Davis JM; Grosu GT; Baker J; Zask A; Levin JI; Ellingboe J; Skotnicki JS; Dijoseph JF; Sung A; Jin G; Xu W; McCarthy DJ; Barone D
J Med Chem; 2004 Dec; 47(25):6255-69. PubMed ID: 15566296
[TBL] [Abstract][Full Text] [Related]
13. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.
Chen JM; Jin G; Sung A; Levin JI
Bioorg Med Chem Lett; 2002 Apr; 12(8):1195-8. PubMed ID: 11934587
[TBL] [Abstract][Full Text] [Related]
14. Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.
Levin JI; Chen JM; Laakso LM; Du M; Du X; Venkatesan AM; Sandanayaka V; Zask A; Xu J; Xu W; Zhang Y; Skotnicki JS
Bioorg Med Chem Lett; 2005 Oct; 15(19):4345-9. PubMed ID: 16084720
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
[TBL] [Abstract][Full Text] [Related]
16. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
Levin JI; Du MT
Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.
Park K; Gopalsamy A; Aplasca A; Ellingboe JW; Xu W; Zhang Y; Levin JI
Bioorg Med Chem; 2009 Jun; 17(11):3857-65. PubMed ID: 19410464
[TBL] [Abstract][Full Text] [Related]
18. Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).
Ott GR; Asakawa N; Lu Z; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Traskos JM; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2008 Jan; 18(2):694-9. PubMed ID: 18061445
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.
Zhu Z; Mazzola R; Sinning L; McKittrick B; Niu X; Lundell D; Sun J; Orth P; Guo Z; Madison V; Ingram R; Beyer BM
J Med Chem; 2008 Feb; 51(4):725-36. PubMed ID: 18247549
[TBL] [Abstract][Full Text] [Related]
20. Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.
Lu Z; Ott GR; Anand R; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Trzaskos J; Duan JJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1958-62. PubMed ID: 18282708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
